Mounjaro and Diabetes: Two Licences, One Pen

You have type 2 diabetes and your GP has mentioned Mounjaro

Your GP is likely thinking about the diabetes licence first. Tirzepatide was approved in the UK for type 2 diabetes management before the weight-management licence arrived, and it works through a dual mechanism that no other medicine in its class shares: it activates both the GIP and GLP-1 receptors involved in blood-sugar regulation and appetite. The BNF entry for tirzepatide sets out the prescribing framework for both indications.

If weight is also a concern, your prescriber may be considering the weight-management licence instead, or alongside existing diabetes treatment. The overlap matters clinically. Combining Mounjaro with certain other glucose-lowering medicines, particularly sulfonylureas or insulin, raises the risk of hypoglycaemia, so those doses often need reviewing before or shortly after starting. This is not a reason to avoid Mounjaro if it is otherwise appropriate; it is a reason to have the conversation with a prescriber who can see your full medication list. You can read more about how Mounjaro is used for type 2 diabetes, including what the licensing means in practice, on our dedicated page covering the diabetes-specific indication. You can also read more about how Mounjaro is used in the management of type 2 diabetes in our dedicated section, including what the licensing means in practice.

At nume, a real clinician reads every consultation the same day. They are not running answers through a decision tree; they review your health history, current medicines, and circumstances before any prescription is written. If your situation involves active diabetes management, they will tell you plainly whether the private weight-management route through us is appropriate or whether your GP or diabetes team should lead.

You have prediabetes and are hoping Mounjaro might help

Prediabetes sits in a clinically interesting position. Under the UK weight-management licence, it is listed as a weight-related condition that can contribute to eligibility for Mounjaro alongside a BMI of 27 or above. The NICE technology appraisal TA1026, which recommends tirzepatide for weight management within the NHS, names prediabetes among the qualifying comorbidities at the lower BMI threshold.

That does not mean prediabetes equals automatic approval. BMI alone does not decide suitability; neither does the condition list. A prescriber weighs the full picture: your other health conditions, medicines, lifestyle, and what you are hoping treatment will achieve. For many people with prediabetes and excess weight, the evidence from the SURMOUNT programme is genuinely encouraging. Meaningful weight loss can, in some cases, help reverse prediabetes progression, though that is a clinical outcome to discuss with your own doctor rather than something to plan around.

Worth knowing: Monday orders placed before 12pm reach our prescribers the same day. If you have been putting off starting the process until after the next payday or a holiday, the timeline is shorter than most people expect. Our free consultation takes minutes; approval, where appropriate, follows the same working day.

You have type 1 diabetes: what the evidence and UK licensing say

This is the clearest answer on the page. Mounjaro is not licensed for type 1 diabetes in the UK. The clinical trials that underpinned both UK licences excluded people with type 1 diabetes, so there is no robust evidence base for its use in that population through either indication. The NHS patient information for tirzepatide makes this explicit.

If you have type 1 diabetes and are managing your weight, the treatment options available to you differ, and the conversation belongs with your endocrinologist or diabetes specialist. Some GLP-1 medicines are used off-label in type 1 diabetes in specialist settings, but that sits well outside what a private online pharmacy is the right route for. We would not prescribe Mounjaro in this situation. Our page on Mounjaro and type 1 diabetes covers this in more detail, including which questions are worth raising with your specialist team.

The same principle applies to situations where the relationship between tirzepatide and diabetes remains genuinely uncertain, such as the question of whether Mounjaro can cause diabetes. These are not questions with a settled one-line answer, and our prescribers would rather you have the full picture than a reassuring oversimplification.

Before starting: what a prescriber needs to know about your diabetes history

Whether your diabetes is current, historical, or at the prediabetes stage, the details matter before any prescription is written. Relevant information includes: your current HbA1c or recent blood-glucose readings, any diabetes medicines you take (including insulin), your kidney function if known, and whether you have a history of pancreatitis or gallbladder disease. The MHRA has highlighted acute pancreatitis as an infrequent but serious risk with GLP-1 medicines; anyone with a history of the condition would need to discuss this carefully with a prescriber before starting tirzepatide.

If you are currently under a diabetes specialist or consultant, letting them know you are considering or starting Mounjaro is good clinical practice. At nume, GP notification is part of the standard process, in line with GPhC guidance. Your GP receiving a letter is not a barrier; it is how joined-up care is supposed to work.

People exploring whether Mounjaro might be a good fit for their broader situation often find our page on whether Mounjaro is effective for diabetes a useful place to start. For a broader overview of the treatment itself, our Mounjaro information page covers the mechanism, the evidence and what the process looks like from a UK perspective. Check your eligibility by starting a free consultation with our prescribers.